Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) fell 6.6% during mid-day trading on Wednesday . The company traded as low as $14.00 and last traded at $14.06. 67,075 shares changed hands during trading, a decline of 68% from the average session volume of 211,837 shares. The stock had previously closed at $15.06.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on MAZE. Wedbush began coverage on shares of Maze Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $17.00 target price on the stock. Guggenheim restated a "buy" rating and set a $19.00 target price on shares of Maze Therapeutics in a research report on Wednesday, April 2nd. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $23.50.
Check Out Our Latest Stock Analysis on MAZE
Maze Therapeutics Trading Down 3.8%
The company's fifty day simple moving average is $11.65.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Hedge Funds Weigh In On Maze Therapeutics
A number of hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in shares of Maze Therapeutics in the 1st quarter valued at $145,000. Rhumbline Advisers acquired a new position in shares of Maze Therapeutics during the 1st quarter valued at $80,000. Woodline Partners LP acquired a new position in shares of Maze Therapeutics during the 1st quarter valued at $10,229,000. Octagon Capital Advisors LP acquired a new position in shares of Maze Therapeutics during the 1st quarter valued at $5,153,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Maze Therapeutics during the 1st quarter valued at $57,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
